

Fig. 2 Dose–response curves for SST-specific signalling activities of SSTR5 with or without additional SS in yeast cells. To examine the effects of SS for the SST-specific SSTR5 signalling, prepro-SSTR5, pre-SSTR5 and Ste2N-SSTR5 were prepared. The signalling activities of recombinant strains MI-170-3 (prepro), MI-170-4 (pre) and MI-170-5 (Ste2N) were evaluated using the *GFP* reporter gene as described in 'MATERIALS AND METHODS' section. **(A)** Pharmacological efficacies of yeast transformants were represented by green-RFU normalized with the green fluorescent intensities of the SST-untreated yeast cells as the reference values, respectively. **(B)** Pharmacological potencies of yeast transformants were represented by relative green-RFU normalized with the values of maximal effects of SST-specific dose responses as the reference values, respectively. MI-170-2 data shown in Fig. 1 are displayed for comparison. Data points represent the mean of triplicate independent experiments and error bars represent the standard deviation.

Table V. Characterization of SSTR5 receptors with and without SS expressed in MI-170 yeast cells.

Receptor	Expression level[a]	Maximal effect[b]	EC_{50} value[c]
SSTR5	2.58 ± 0.54	20.1 ± 0.74	3.17×10^{-7}
Prepro-SSTR5	4.81 ± 0.99	10.2 ± 0.62	2.92×10^{-7}
Pre-SSTR5	6.12 ± 0.49	11.9 ± 0.76	1.37×10^{-7}
Ste2N-SSTR5	8.43 ± 1.37	12.7 ± 1.1	1.01×10^{-7}

[a]Expression levels cited the values in Fig. 3.
[b]Maximal effects cited the values in Fig. 2A.
[c]EC_{50} values cited the values in Fig. 2B.

to functionally couple the SSTR5 to the yeast pheromone signalling pathway as shown in a previous report (*19*). Obviously, the maximum effect responding to the highest concentration of SST was enhanced in the Gi3tp-expressing yeast cells and the dose–response curves exposed the suitable pharmacological potency and efficacy of Gi3tp for the SSTR5 (Fig. 1). Therefore, the SSTR5 Gα-subunit was successfully optimised by substitution of chimeric Gi3tp for endogenous Gpa1 in the yeast-based fluorescent signalling assay system. Although productivity and transportation of the heterogous GPCRs could be enhanced via introduction of the yeast SS in yeast cells (*12*, *15*, *16*), the signalling functions of SS-attached GPCRs have been rarely described. When constructing a superior ligand screening method using a yeast-based fluorescent signalling assay system, either higher sensitivity or a higher maximal effect should be achieved in the system, although it is difficult to simultaneously achieve both. Indeed, the signalling properties desired in yeast-based signalling assay systems differ depending on the aims for varied assay applications. For example, systems with high sensitivity are useful for the agonist detection assay at low concentrations or the competitive assay



Fig. 3 Estimation of expression levels of CFP-fluorescent tagged SSTR5 receptors with or without additional SS sequences. Four CFP-fluorescent tagged SSTR5 constructs—SSTR5-CFP, prepro-SSTR5-CFP, pre-SSTR5-CFP and Ste2N-SSTR5-CFP—were prepared to generate recombinant strains MI-170-6 (SSTR5), MI-170-7 (prepro), MI-170-8 (pre) and MI-170-9 (Ste2N), respectively. Cellular cyan-RFU was calculated as described in 'MATERIALS AND METHODS' section. Data represent the mean of triplicate independent experiments and error bars represent the standard deviation.

with antagonists; on the other hand, systems with high maximal effect are useful for the high-throughput ligand screening system by FACS. By controlling the signalling property, we could construct a suitable yeast-based assay system depending on the aims of the assays. Therefore, to control signalling ability of human SSTR5 in a yeast-based signalling assay system, we constructed four types of SSTR5 receptor variants and investigated their SST-specific signalling activities in yeast cells.

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010



Fig. 4 Observation of localisation patterns of CFP-fluorescent tagged SSTR5 receptors with or without additional SS. The yeast strain MI-170 was used as the host strain to introduce CFP-fluorescent tagged SSTR5 receptors without or with additional SS. Four CFP-fluorescent tagged SSTR5 constructs—SSTR5-CFP, prepro-SSTR5-CFP, pre-SSTR5-CFP and Ste2N-SSTR5-CFP—were prepared to generate recombinant strains MI-170-6 (SSTR5), MI-170-7 (prepro), MI-170-8 (pre) and MI-170-9 (Ste2N), respectively. The cellular cyan fluorescence was observed with the fluorescence microscope as described in 'MATERIALS AND METHODS' section. White bars represent 10 μm.

Insertions of any three SS to the amino-terminus of SSTR5 drastically decreased the efficacies of the engineered receptors expressing cells compared to that of the native SSTR5 form (Fig. 2A and Table V). The pharmacological potencies of SST for the engineered SS-SSTR5 receptors were higher than that of the native form SSTR5 receptor; Ste2N-SSTR5 in particular displayed the highest potency for SST-dependent signalling activity (Fig. 2B and Table V). Therefore, the Ste2N-SSTR5 receptor is useful for constructing high-sensitivity yeast-based assay systems such as agonist detection assays at low concentrations and competitive assays with antagonists.

FACS analysis of the CFP fusion proteins indicated that addition of SS increased SSTR5 expression levels in yeast cells (Fig. 3). However, not all of the CFP-tagged SSTR5 molecules were localised to the plasma membrane because the CFP-tagged SSTR5 molecules were transported by different protein sorting pathways depending on the SS properties (Fig. 4). These results suggest that the SS of the typical secretory protein is not suitable for functional expression of seven transmembrane SSTR5 receptors at the yeast plasma membrane. The potency was decreased in the case of prepro-SSTR5, which may be caused by the lower amount of the receptors on yeast cell surface.

The large amounts of SSTR5 receptors at the yeast plasma membrane accelerate the ligand binding even low concentration of SST, as a result, the potency of Ste2N-SSTR5 was improved. Although ligand binding ability seemed to effect on the efficacy, Sander *et al.* (*16*) reported the introduction of Ste2-derived SS to human D_{2s} dopamine receptor did not affect the ligand binding ability when the receptor was expressed on the yeast cell surface. Therefore, we assumed the binding ability of SS-attached SSTR5 is almost same as that of SSTR5. One of the possible explanations for decreased efficacy is that introduction of SS at amino-terminus may inhibit the receptor dimerisation (*20*, *21*). Dimerisation of GPCRs should be required for desensitisation and internalisation, which are necessary events to refresh ligand-bound receptors and regenerate ligand-free receptors at the plasma membrane for responding to the redundant extracellular ligands (*22*, *23*).

In conclusion, we demonstrated SST-specific signalling functions of SSTR5 via introduction of SSs in yeast. Using a yeast–human Gi3tp chimera, we optimised the yeast-based fluorescent assay system. Introduction of Ste2N to the amino-terminus of human SSTR5 significantly improved pharmaceutical potency in the yeast-based fluorescent assay system. This finding will be an informative support to

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010

construct optimal yeast-based flow cytometric signalling assay systems using other human GPCRs and will be helpful for execution of primary drug screening.

Acknowledgements

The authors thank Prof. Shun'ichi Kuroda and Dr Kenji Tatematsu for their help.

Funding

This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas (Life surveyor) and in part by a Special Coordination Funds for Promoting Science and Technology, Creation of Innovation Centres for Advanced Interdisciplinary Research Areas (Innovative Bioproduction Kobe) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and was funded in part by AS ONE Corporation.

Conflict of interest

None declared.

References

1. Wise, A., Gearing, K., and Rees, S. (2002) Target validation of G-protein coupled receptors. *Drug Discov. Today* **7**, 235–246
2. Reisine, T. and Bell, G. (1995) Molecular biology of somatostatin receptors. *Endocr. Rev.* **16**, 427–442
3. Shimon, I., Taylor, J.E., Dong, J.Z., Bitonte, R.A., Kim, S., Morgan, B., Coy, D.H., Culler, M.D., and Melmed, S. (1997) Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. *J. Clin. Invest.* **99**, 789–798
4. Casarini, A.P., Jallad, R.S., Pinto, E.M., Soares, I.C., Nonogaki, S., Giannella-Neto, D., Musolino, N.R., Alves, V.A., and Bronstein, M.D. (2009) Acromegaly: correlation between expression of somatostatin receptor subtypes and response to octreotide-lar treatment. *Pituitary* **12**, 297–303
5. Duran-Prado, M., Gahete, M.D., Martinez-Fuentes, A.J., Luque, R.M., Quintero, A., Webb, S.M., Benito-Lopez, P., Leal, A., Schulz, S., Gracia-Navarro, F., Malagon, M.M., and Castano, J.P. (2009) Identification and characterization of two novel truncated but functional isoforms of the somatostatin receptor subtype 5 differentially present in pituitary tumors. *J. Clin. Endocrinol. Metab.* **94**, 2634–2643
6. Vieira Neto, L., Taboada, G.F., and Gadelha, M.R. (2008) Somatostatin receptors subtypes 2 and 5, dopamine receptor type 2 expression and *gsp* status as predictors of octreotide LAR responsiveness in acromegaly. *Arq. Bras. Endocrinol. Metabol.* **52**, 1288–1295
7. Dowell, S.J. and Brown, A.J. (2002) Yeast assays for G-protein-coupled receptors. *Receptors Channels* **8**, 343–352
8. Ladds, G., Goddard, A., and Davey, J. (2005) Functional analysis of heterologous GPCR signalling pathways in yeast. *Trends Biotechnol.* **23**, 367–373
9. Klco, J.M., Nikiforovich, G.V., and Baranski, T.J. (2006) Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WXFG motif in the first loop. *J. Biol. Chem.* **281**, 12010–12019
10. Minic, J., Sautel, M., Salesse, R., and Pajot-Augy, E. (2005) Yeast system as a screening tool for pharmacological assessment of G protein coupled receptors. *Curr. Med. Chem.* **12**, 961–969
11. Scarselli, M., Li, B., Kim, S.K., and Wess, J. (2007) Multiple residues in the second extracellular loop are critical for M_3 muscarinic acetylcholine receptor activation. *J. Biol. Chem.* **282**, 7385–7396
12. Yellen, G. and Migeon, J.C. (1990) Expression of Torpedo nicotinic acetylcholine receptor subunits in yeast is enhanced by use of yeast signal sequences. *Gene* **86**, 145–152
13. Tanino, T., Matsumoto, T., Fukuda, H., and Kondo, A. (2004) Construction of system for localization of target protein in yeast periplasm using invertase. *J. Mol. Catal. B: Enzymatic* **28**, 259–264
14. Yamada, R., Bito, Y., Adachi, T., Tanaka, T., Ogino, C., Fukuda, H., and Kondo, A. (2009) Efficient production of ethanol from raw starch by a mated diploid *Saccharomyces cerevisiae* with integrated α-amylase and glucoamylase genes. *Enzyme & Microbial. Technol.* **44**, 344–349
15. King, K., Dohlman, H.G., Thorner, J., Caron, M.G., and Lefkowitz, R.J. (1990) Control of yeast mating signal transduction by a mammalian β_2-adrenergic receptor and G_s α subunit. *Science* **250**, 121–123
16. Sander, P., Grunewald, S., Bach, M., Haase, W., Reilander, H., and Michel, H. (1994) Heterologous expression of the human D_{2S} dopamine receptor in protease-deficient *Saccharomyces cerevisiae* strains. *Eur. J. Biochem.* **226**, 697–705
17. Akada, R., Kitagawa, T., Kaneko, S., Toyonaga, D., Ito, S., Kakihara, Y., Hoshida, H., Morimura, S., Kondo, A., and Kida, K. (2006) PCR-mediated seamless gene deletion and marker recycling in *Saccharomyces cerevisiae*. *Yeast* **23**, 399–405
18. Gietz, D., St Jean, A., Woods, R.A., and Schiestl, R.H. (1992) Improved method for high efficiency transformation of intact yeast cells. *Nucleic Acids Res.* **20**, 1425
19. Brown, A.J., Dyos, S.L., Whiteway, M.S., White, J.H., Watson, M.A., Marzioch, M., Clare, J.J., Cousens, D.J., Paddon, C., Plumpton, C., Romanos, M.A., and Dowell, S.J. (2000) Functional coupling of mammalian receptors to the yeast mating pathway using novel yeast/mammalian G protein α-subunit chimeras. *Yeast* **16**, 11–22
20. Overton, M.C. and Blumer, K.J. (2002) The extracellular N-terminal domain and transmembrane domains 1 and 2 mediate oligomerization of a yeast G protein-coupled receptor. *J. Biol. Chem.* **277**, 41463–41472
21. Milligan, G. (2009) G protein-coupled receptor hetero-dimerization: contribution to pharmacology and function. *Br. J. Pharmacol.* **158**, 5–14
22. Watt, H.L., Kharmate, G.D., and Kumar, U. (2009) Somatostatin receptors 1 and 5 heterodimerize with epidermal growth factor receptor: agonist-dependent modulation of the downstream MAPK signalling pathway in breast cancer cells. *Cell Signal.* **21**, 428–439
23. Stroh, T., Jackson, A.C., Sarret, P., Dal Farra, C., Vincent, J.P., Kreienkamp, H.J., Mazella, J., and Beaudet, A. (2000) Intracellular dynamics of sst_5 receptors in transfected COS-7 cells: maintenance of cell surface receptors during ligand-induced endocytosis. *Endocrinology* **141**, 354–365
24. Brachmann, C.B., Davies, A., Cost, G.J., Caputo, E., Li, J., Hieter, P., and Boeke, J.D. (1998) Designer deletion strains derived from *Saccharomyces cerevisiae* S288C: a useful set of strains and plasmids for PCR-mediated gene disruption and other applications. *Yeast* **14**, 115–132
25. Winzeler, E.A., Shoemaker, D.D., Astromoff, A., Liang, H., Anderson, K., Andre, B., Bangham, R., Benito, R., Boeke, J.D., Bussey, H., Chu, A.M., Connelly, C., Davis,

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010

K., Dietrich, F., Dow, S.W., El Bakkoury, M., Foury, F., Friend, S.H., Gentalen, E., Giaever, G., Hegemann, J.H., Jones, T., Laub, M., Liao, H., Liebundguth, N., Lockhart, D.J., Lucau-Danila, A., Lussier, M., M'Rabet, N., Menard, P., Mittmann, M., Pai, C., Rebischung, C., Revuelta, J.L., Riles, L., Roberts, C.J., Ross-MacDonald, P., Scherens, B., Snyder, M., Sookhai-Mahadeo, S., Storms, R.K., Veronneau, S., Voet, M., Volckaert, G., Ward, T.R., Wysocki, R., Yen, G.S., Yu, K., Zimmermann, K., Philippsen, P., Johnston, M., and Davis, R.W. (1999) Functional characterization of the *S. cerevisiae* genome by gene deletion and parallel analysis. *Science* **285**, 901–906

26. Sato, N., Matsumoto, T., Ueda, M., Tanaka, A., Fukuda, H., and Kondo, A. (2002) Long anchor using Flo1 protein enhances reactivity of cell surface-displayed glucoamylase to polymer substrates. *Appl. Microbiol. Biotechnol.* **60**, 469–474
27. Ishii, J., Tanaka, T., Matsumura, S., Tatematsu, K., Kuroda, S., Ogino, C., Fukuda, H., and Kondo, A. (2008) Yeast-based fluorescence reporter assay of G protein-coupled receptor signalling for flow cytometric screening: *FAR1*-disruption recovers loss of episomal plasmid caused by signalling in yeast. *J. Biochem.* **143**, 667–674
28. Ishii, J., Izawa, K., Matsumura, S., Wakamura, K., Tanino, T., Tanaka, T., Ogino, C., Fukuda, H., and Kondo, A. (2009) A simple and immediate method for simultaneously evaluating expression level and plasmid maintenance in yeast. *J. Biochem.* **145**, 701–708

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010

J. Biochem. 2010;147(6):867–873 doi:10.1093/jb/mvq022

JB THE JOURNAL OF BIOCHEMISTRY

Importance of asparagine residues at positions 13 and 26 on the amino-terminal domain of human somatostatin receptor subtype-5 in signalling

Received January 7, 2010; accepted February 22, 2010; published online March 5, 2010

Shota Togawa[1], Jun Ishii[2], Atsushi Ishikura[1], Tsutomu Tanaka[2], Chiaki Ogino[1] and Akihiko Kondo[1,*]

[1]Department of Chemical Science and Engineering, Graduate School of Engineering; and [2]Organization of Advanced Science and Technology, Kobe University, Japan

*Akihiko Kondo, Department of Chemical Science and Engineering, Graduate School of Engineering, Kobe University, 1-1 Rokkodaicho, Nada-ku, Kobe 657-8501, Japan. Tel./Fax: +81 78 803 6196, e-mail: akondo@kobe-u.ac.jp

N-linked oligosaccharides or asparagine residues are often involved in G protein-coupled receptor functions. Focusing on Asn13 and Asn26 positioned on N-linked glycosylation motifs in the amino-terminal domain of human somatostatin receptor subtype-5 (hSSTR5), we performed site-directed mutagenesis and evaluated the mutants by using yeast cells as the host strain. This is because analysing the complicated signalling in mammalian cell lines is simplified by the utilization of the monopolistic pheromone signalling pathway in yeast. Western blot analysis and confocal laser scanning microscope observation showed that Asn13 and/or Asn26 mutations had no effects on cell-surface expression of hSSTR5 in yeast. By using an engineered yeast strain of *Saccharomyces cerevisiae*, which induces the expression of the green fluorescent protein (*GFP*) reporter gene in response to the agonist-specific signal transduction, it was demonstrated that a single mutation of two asparagine residues attenuated the somatostatin-specific signalling levels, and the double mutant significantly lost the signalling ability. These results clearly show the importance of these asparagine residues in the agonist-specific signalling of hSSTR5, although it was not enough to identify the consequence of oligosaccharides.

Keywords: G protein-coupled receptor/green fluorescent protein/mutagenesis/somatostatin receptor/yeast.

Abbreviations: *EGFP*, enhanced green fluorescent protein; FDA, Food and Drug Administration; 5-FOA, 5-fluoroorotic acid; GFP, green fluorescent protein; G-proteins, guanine nucleotide binding proteins; GPCR, G protein-coupled receptor; hSSTR5, human somatostatin receptor subtype-5; 2-ME, 2-mercaptoethanol; *PGK3'*, *PGK1* terminator; *PGK5'*, *PGK1* promoter; PMSF, phenylmethylsulphonyl fluoride; SD, synthetic dextrose; SSTR, somatostatin receptor; YPD, yeast extract–peptone–dextrose.

G protein-coupled receptors (GPCRs) constitute the largest family of transmembrane receptors and are considered attractive for pharmaceutical and therapeutic targets in the field of drug discovery. Currently, nearly 30% of Food and Drug Administration (FDA)-approved drugs are modulators of GPCR function (*1*). These receptors transduce the external stimuli and the binding of ligands into intracellular signals, which underlie a variety of biological processes, via the intracellular guanine nucleotide-binding proteins (G-proteins) (*2*, *3*). The heterotrimeric G-proteins universally comprise the Gα, Gβ and Gγ-subunits and are classified into various classes in humans—many GPCRs, by using complex mechanisms, activate the various signalling pathways through these peripheral G-proteins.

The budding yeast *Saccharomyces cerevisiae* is a familiar host cell system to study GPCRs because it simplifies the analyses of the complicated signalling in mammalian cell lines (*4*). The yeast possesses the uncompetitive and monopolistic G-protein signalling pathway (pheromone-signalling pathway), and it has successfully coupled a variety of human GPCRs to the yeast pheromone signalling pathway via the sole endogenous Gα-subunit (*5*). Therefore, the ligand-specific activation of human GPCRs is detectable by several types of reporter genes, which are expressed when the pheromone responsible promoters are utilized in responding to the ligand-specific stimulation via pheromone signalling (*6*, *7*). Several mutagenesis studies investigating the important domains on human GPCRs in yeasts have demonstrated that the yeast cells are convenient tools to determine the critical amino-acid residues for their functions (*8*–*10*).

Somatostatin, a cyclic neuropeptide known as a growth hormone release-inhibiting factor, is a natural ligand of somatostatin receptors. Five subtypes of somatostatin receptors have been identified (SSTR1–SSTR5) (*11*, *12*), and they are noticeable for therapeutic targets of acromegaly, Cushing's disease and Alzheimer's disease (*13*–*15*). They are widely expressed in several organs with tissue-specific distribution patterns; SSTR2 and SSTR5, in particular, predominantly regulate growth-hormone secretion in acromegaly patients (*16*). Therefore, information on the structural differences of these receptors might be attractive for subtype-specific drug designs or the presumption of significant mutations involved in these diseases.

GPCRs are typical heptahelical receptors, and they are composed of an extracellular amino-terminus, an

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010

© The Authors 2010. Published by Oxford University Press on behalf of the Japanese Biochemical Society. All rights reserved

intracellular carboxy-terminus and seven transmembrane bundles, which are connected by three intracellular loops and three extracellular loops. A wide variety of motifs and amino-acid residues in these domains characterize the structural roles of GPCRs with receptor-specific differentiations. The consensus sequences for N-linked glycosylation (Asn-X-Thr or Asn-X-Ser) in which oligosaccharides could bind to the asparagine residues (*17*) are found in many GPCRs and are shared by almost all eukaryotes, including yeast cells (*18*). The significance of these asparagine residues has been demonstrated in various receptors and they seem to play several important roles, for example, in ligand affinity, and plasma membrane localisation and signalling activation, although the role varies with (i) the receptor type addressing the functions, (ii) the N-linked oligosaccharides, (iii) or the side chains of asparagine residues themselves (*19–22*). In the case of human SSTRs, the extracellular amino-terminal domain of all subtypes (SSTR1–5) certainly includes one or more N-glycosylation sites (*23*). Mutations of Asn18 and Asn31 residues on the N-glycosylation sites in rat SSTR3 affect somatostatin ligand binding and the inhibition of adenylyl cyclase activity in signal transduction (*24*). However, there are no reports on the mutagenesis of human SSTRs on these sites. Therefore, we focused on the 13th and 26th asparagine residues forming the N-glycosylation motifs on the amino-terminal domain of human SSTR5 (hSSTR5) because of the lower affinity of available therapeutic medicine, octreotide and lanreotide to SSTR5 than to SSTR2 (*15*).

In this study, we performed site-directed mutagenesis of asparagine residues on the two N-linked glycosylation motifs in the amino-terminal domain of hSSTR5. The alanine residues were substituted for Asn13 and Asn26 residues in the amino-terminal domain of hSSTR5, and the mutants were analysed for expression, localisation and signalling activity. In order to quantitatively estimate the signalling activity of the receptors, the yeast *S. cerevisiae* was selected as the host, and the engineered yeast strain was constructed to induce the expression of the *GFP* reporter gene responding to ligand binding (*25*). Through this work, we show that the double substitution of asparagine residues on the N-glycosylation motifs in the amino-terminus of hSSTR5 significantly decreases the signalling activity, and we also show the availability of a yeast-based fluorescent assay for GPCR signalling analysis.

Materials and Methods

Yeast strain

The yeast strain IMFD-70 (*MAT*a *leu2*Δ*0 met15*Δ*0 ura3*Δ*0 far1*Δ *sst2*Δ::*AUR1-C ste2*Δ::*LEU2 fig1*Δ::*EGFP his3*Δ::P_{FIG1}-*EGFP*) was used in this assay. This strain was derived from BY4741 and was constructed as follows. Each linear DNA fragment was introduced into yeasts using the lithium acetate method (*26*). In accordance with the marker recycling method, the *URA3* marker was eliminated by homologous recombination, using counter selection in each transformation step (*27*). The oligonucleotides used in this study were summarised in Table I. The strains and plasmids were summarised in Table II.

The plasmid used for substituting the fluorescence reporter gene for the *FIG1* gene on the yeast chromosome was constructed as follows: DNA fragments encoding the *FIG1* promoter (300 bp) and *FIG1* terminator (300 bp) were amplified by PCR from BY4741 genomic DNA with the following oligonucleotide pairs: o1 and o2; and o3 and o4. The amplified fragments were, respectively, digested with *Eco*RI/*Bam*HI and *Bam*HI/*Sph*I and ligated at the *Eco*RI/*Sph*I sites on pCR4 Blunt-TOPO vector (Invitrogen, Carlsbad, CA). The resultant plasmid was named pFIG1pt. A DNA fragment encoding the enhanced green fluorescent protein (*EGFP*) gene was amplified from pEGFP (Takara Bio, Shiga, Japan) by PCR with the oligonucleotides o5 and o6. The amplified fragment was digested with *Bgl*II/*Bam*HI and ligated at the *Bam*HI site on pFIG1pt. The resultant plasmid was named pFIG1GF. A DNA fragment encoding the *URA3* selectable marker (with 40 nucleotides from the 5′-side of the *FIG1* terminator at the 5′-end) was amplified by PCR from pRS426 (American Type Culture Collection, Manassas, VA) with oligonucleotides o7 and o8. The amplified fragment was digested with *Bam*HI and ligated at the same site on pFIG1GF. The resultant plasmid was named pMR-FIG1GF. A DNA fragment encoding the *FIG1* promoter (450 bp) and a DNA fragment encoding the *EGFP* gene, *URA3* selectable marker, and *FIG1* terminator were amplified by PCR from BY4741 genomic DNA and pMR-FIG1GF with the following oligonucleotide pairs: o9 and o10; and o4 and o5. The amplified fragments were digested with *Eco*RI/*Bam*HI and *Bgl*II/*Sph*I and ligated at the *Eco*RI/*Sph*I sites on the pUC119 vector (Takara Bio). The resultant plasmid was named pFIG450GF. Two DNA fragments encoding the homologous sequence of the *HIS3* locus were amplified from the BY4741 genomic DNA with the following oligonucleotide pairs: o11 and o12; and o13 and o14, and a DNA fragment containing the *FIG1* promoter, *EGFP* gene, 40 nucleotides (of *FIG1* terminator), the *URA3* selectable marker and *FIG1* terminator was amplified from pFIG450GF with oligonucleotides o15 and o16. A DNA fragment was amplified by overlap PCR, using three amplified fragments as templates with oligonucleotides o11 and o14. The amplified fragment was digested with *Eco*RI/*Sph*I and ligated at the same sites on the pUC19 vector (Takara Bio). The resultant plasmid was named pHIS3-FIG1GF.

A DNA fragment containing the *FIG1* promoter, *EGFP* gene, 40 nucleotides (of *FIG1* terminator), *URA3* selectable marker and *FIG1* terminator was amplified by PCR from pMR-FIG1GF with oligonucleotides o17 and o18, and the amplified fragment was introduced into IM-50 (*25*). After confirming correct integration, the *URA3* marker was eliminated by homologous recombination using counter selection with 5-fluoroorotic acid (5-FOA; Fluorochem, Derbyshire, UK). The strain substituted with the *EGFP* gene for the *FIG1* gene was designated IMF-50. A DNA fragment containing a homologous sequence of the *HIS3* terminator region, *FIG1* promoter, *EGFP* gene, 40 nucleotides (of *FIG1* terminator), *URA3* selectable marker, *FIG1* terminator and a homologous sequence of the *HIS3* promoter region were prepared by digestion of pHIS3-FIG1GF with *Eco*RI/*Sph*I, and the fragment was introduced into IMF-50. After confirming correct integration, the *URA3* marker was eliminated by counter selection with 5-FOA, and the strain integrated with P_{FIG1}-*EGFP*-T_{FIG1} into the *HIS3* locus was designated IMFD-50.

A DNA fragment encoding the *URA3* selectable marker (containing a homologous sequence to delete the *FAR1* gene and one to eliminate the *URA3* marker) was amplified from pRS426 with oligonucleotides o19 and o20, and a DNA fragment encoding the *FAR1* terminator region was amplified from BY4741 genomic DNA with oligonucleotides o21 and o22. A DNA fragment was amplified by overlap PCR, using two amplified fragments as templates with oligonucleotides o19 and o22, and the amplified fragment was introduced into IMFD-50. After confirming correct integration, the *URA3* marker was eliminated by counter selection with 5-FOA. The constructed strain, whose *FAR1* gene was disrupted, was designated IMFD-70.

Media

The strain was cultured in a YPD medium [containing 1% yeast extract (Nacalai Tesque, Kyoto, Japan), 2% peptone and 2% glucose; w/v] or an SD medium [containing 0.67% yeast nitrogen base without amino acids (Becton, Dickinson and Co., Franklin Lakes, NJ) and 2% glucose; w/v]. The SD medium was supplemented with appropriate amino acids depending on the desired selectable marker (20 mg/l histidine, 60 mg/l leucine and 20 mg/l methionine or 20 mg/l

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010

Table I. Oligonucleotides.

Oligonucleotide	Sequence
o1	5′-GGGGGAATTCTACAAAAATTATAACATTTT-3′
o2	5′-CCCCGGATCCTTTTTTTTTTTTTTTTTTGT-3′
o3	5′-GGGGGGATCCTTTTATCCTCAAATAAACAT-3′
o4	5′-CCCCGCATGCATAACATTAGTATTTATAAA-3′
o5	5′-CTTTAGATCTATGGTGAGCAAGGGCGAGGA-3′
o6	5′-CCCCGGATCCTTACTTGTACAGCTCGTCCA-3′
o7	5′-GGGGGGATCCTTTTATCCTCAAATAAACATAT AAGTTTTGAGCGGATATTTTTTTTGTTCTTTTTT TTGATTCCGGTTTC-3′
o8	5′-CCCCGGATCCGGGTAATAACTGATATAATT-3′
o9	5′-GGGAGAATTCATCACCCTGCATTGCCTCTT-3′
o10	5′-CCCCGGATCCTTTTTTTTTTTTTTTTTTGTTTG TTTGTTTGTTTGTTTAC3′
o11	5′-CCCCGAATTCCGAGTTCAAGAGAAAAAAAA-3′
o12	5′-GCAATGCAGGGTGATTGACACCGATTATTT-3′
o13	5′-AAATACTAATGTTATCTTTGCCTTCGTTTA-3′
o14	5′-GAAAGCATGCTCTTGGCCTCCTCTAGTACA-3′
o15	5′-AAATAATCGGTGTCAATCACCCTGCATTGC-3′
o16	5′-TAAACGAAGGCAAAGATAACATTAGTATTT-3′
o17	5′-TAAGATTATGATGGTTTCATGTATGTGTCA-3′
o18	5′-TTAGTCGCTCATCAAGGTGACAGTAAATAA-3′
o19	5′-CCACTGGAAAGCTTCGTGGGCGTAAGAAGG CAATCTATTATAGTTCGGGAATCGAGGCCCG TATTTCGAGGCTTTTGCTTTTTTTTGTTCTTTT TTTTGA-3′
o20	5-′AAGCAAAAGCCTCGAAATACGGGCCTCGAT TCCCGAACTAGGGTAATAACTGATATAATT-3′
o21	5′-GTATTTCGAGGCTTTTGCTTTTCCTTTTTT-3′
o22	5′-GCATATATGACGAGATTTAATTATCGCCAA-3′
o23	5′-TTTTGCTAGCATGGAGCCCCTGTT-3′
o24	5′-TTGGAGATCTTCAAGCGTAATCTGGAACATC GTATGGGTACAGCTTGCTGGTCTG-3′
o25	5′-GCCTCCACGCCCAGCTGGGCCGCCTCCTCCCCGGGGGCT-3′
o26	5′-AGCCCCCGGGGAGGAGGCGGCCCAGCTGGGCGTGGAGGC-3′
o27	5′-GCCTCTGGAGGCGGTGACGCCAGGACGCTGGTGGGGCCG-3′
o28	5′-CGGCCCCACCAGCGTCCTGGCGTCACCGCCTCCAGAGGC-3′
o29	5′-TTTTGGATCCGTGAGCAAGGGCGAGGAGCT-3′
o30	5′-GGGGAGATCTTTACTTGTACAGCTCGTCCA-3′
o31	5′-TTTTGCTAGCATGGAGCCCCTGTTCCCAGC-3′
o32	5′-GGGAAGATCTCAGCTTGCTGGTCTGCATAA-3′

Underlined sequences indicate complementary pairs for overlap PCR.

uracil and without amino acids for auxotrophic selectivity). In accordance with the signalling assay, the SD medium was adjusted to pH 7.1 with the MOPSO buffer to attain a final concentration of 200 mM and was named SDM71. For solid media, 2% agar was added to the media described above.

Plasmid construction and transformation

The plasmids used for the expression of hSSTR5 were constructed as follows. A DNA fragment encoding the 2 μ origin was prepared by digesting pRS402 + 2 µm (*28*) with *Aat*II and was ligated with the same site into pRS401 (American Type Culture Collection), resulting in pRS401 + 2 µm. The fragment containing the *PGK1* promoter (*PGK5′*), multiple cloning site (*MCS*) and *PGK1* terminator (*PGK3′*) was prepared by digesting pTA2-PGK (*28*) with the *Xho*I and *Not*I sites, and then ligated with the same sites into the pRS401 + 2 µm, producing pGK421. A DNA fragment encoding the *hSSTR5* gene containing the HA tag at the carboxy terminus was amplified from the human brain cDNA library (Invitrogen) with oligonucleotides o23 and o24. The amplified fragment was inserted into pBlueScript II KS (+) vector (Stratagene, La Jolla, CA) at the *Eco*RV site. The resultant plasmid was named pBlue-SSTR5-HA. The plasmid was digested with *Nhe*I/*Bgl*II and ligated into pGK421. The resultant plasmid was named pGK-SSTR5-HA.

Site-directed mutagenesis was carried out using a Quikchange Site-directed mutagenesis kit (Stratagene) according to the manufacturers' protocol. The plasmid pBlue-SSTR5-HA was used as a template with the following primers: o25 and o26 for N13A mutation and o27 and o28 for N26A mutation. The resultant plasmids were named pBlue-SSTR5-N13A and pBlue-SSTR5-N26A, respectively. Using the plasmid pBlue-SSTR5-N13A as the template, site-directed mutagenesis was carried out with the primers o27 and o28. The resultant plasmid was named pBlue-SSTR5-N13/26A. The DNA fragments encoding the mutated *hSSTR5* gene was digested with *Nhe*I/*Bgl*II and ligated into pGK421. The resultant plasmids were named pGK-SSTR5-N13A, pGK-SSTR5-N26A and pGK-SSTR5-N13/26A.

A DNA fragment encoding the *EGFP* gene was amplified by PCR from pEGFP (Takara Bio) with oligonucleotides o29 and o30. The amplified fragment was digested with *Bam*HI/*Bgl*II and ligated at the same sites on pGK421. The resultant plasmid was named pGK421-C-GFP. The DNA fragments encoding the wild-type or mutated *hSSTR5* were amplified by PCR from pBlue-SSTR5-HA, N13A, N26A and N13/26A with oligonucleotides o31 and o32. The amplified fragment was digested with *Nhe*I/*Bgl*II and ligated at the *Nhe*I/*Bam*HI sites on pGK421-C-GFP. The resultant plasmids were named pSSTR5-HA, pSSTR5-N13A-GF, pSSTR5-N26A-GF and pSSTR5-N13/26A-GF. Transformation of IMFD-70 by each plasmid was carried out by the lithium acetate method (*26*).

Cultivation of yeast cell-expressing hSSTR5 mutants

The yeast strain IMFD-70 transformed with the wild-type or mutated hSSTR5 expression plasmid was grown in appropriate auxotrophic SD media at 30°C overnight. The cells were inoculated

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010

Table II. Strains and plasmids.

Yeast strain or plasmid	Description
BY4741	*MAT***a** *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0*
IM-50	*MAT***a** *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 sst2Δ::AUR1-C ste2Δ::LEU2*
IMF-50	*MAT***a** *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 sst2Δ::AUR1-C ste2Δ::LEU2 fig1Δ::EGFP*
IMFD-50	*MAT***a** *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 sst2Δ::AUR1-C ste2Δ::LEU2 fig1Δ::EGFP his3Δ::*P_{FIG1}*-EGFP*
IMFD-70	*MAT***a** *his3Δ1 leu2Δ0 met15Δ0 ura3Δ0 sst2Δ::AUR1-C ste2Δ::LEU2 fig1Δ::EGFP his3Δ::*P_{FIG1}*-EGFP far1Δ*
pFIG1pt	P_{FIG1}*(300 bp)-*T_{FIG} in pCR4 Blunt-TOPO
pFIG1GF	P_{FIG1}*(300 bp)-EGFP-*T_{FIG1} in pFIG1pt
pMR-FIG1GF	P_{FIG1}*(300 bp)-EGFP-URA3-*T_{FIG1} in pFIG1GF [for generating *fig1Δ::EGFP* in IM-50]
pFIG450GF	P_{FIG1}*(450 bp)-EGFP-URA3-*T_{FIG1} in pUC119
pHIS3-FIG1GF	*HIS3(3'flanking region)-*P_{FIG1}*(450 bp)-EGFP-URA3-*T_{FIG1}*-HIS3(5'flanking region)* in pUC119 [for generating *his3Δ::*P_{FIG1}*-EGFP* in IMF-50]
pGK421	Yeast expression vector containing *PGK1* promoter, 2μ *ori* and *MET15* marker
pBlue-SSTR5-HA	*hSSTR5-HA* in pBluescript II KS (+)
pGK-SSTR5-HA	*hSSTR5-HA* in pGK421
pBlue-SSTR5-N13A	*hSSTR5(N13A)-HA* mutant in pBluescript II KS (+)
pBlue-SSTR5-N26A	*hSSTR5(N26A)-HA* mutant in pBluescript II KS (+)
pBlue-SSTR5-N13/26A	*hSSTR5(N13/26A)-HA* mutant in pBluescript II KS (+)
pGK-SSTR5-N13A	*hSSTR5(N13A)-HA* mutant in pGK421
pGK-SSTR5-N26A	*hSSTR5(N26A)-HA* mutant in pGK421
pGK-SSTR5-N13/26A	*hSSTR5(N13/26A)-HA* mutant in pGK421
pGK421-C-GFP	*EGFP* in pGK421
pSSTR5-GF	*hSSTR5-EGFP* in pGK421
pSSTR5-N13A-GF	*hSSTR5(N13A)-EGFP* in pGK421
pSSTR5-N26A-GF	*hSSTR5(N26A)-EGFP* in pGK421
pSSTR5-N13/26A-GF	*hSSTR5(N13/26A)-EGFP* in pGK421

Underlined strain and plasmids were used for assays.

into appropriate auxotrophic SD media to yield an initial optical density of 0.03 at 600 nm, and the cells were grown at 30°C for 18 h.

Western blot analysis

The cultured cells were suspended in 10 mM Tris–HCl (pH 7.8) containing 1 mM phenylmethylsulphonyl fluoride (PMSF) to yield an optical density of 50 at 600 nm, and 200 μl of the cell suspensions was disrupted using multi-beads shocker (Yasui Kikai, Osaka, Japan) with 0.5-mm glass beads. The cell lysate was centrifuged at 1,000*g* for 5 min, and the pellet was washed three times with 10 mM Tris–HCl (pH 7.8) containing 1 mM PMSF. The pellet was re-suspended with 200 μl of buffer [50 mM Tris–HCl (pH 7.8), 2% (w/v) SDS, 100 mM EDTA, 40 mM 2-mercaptoethanol (2-ME)], and the suspension was boiled at 95°C for 5 min and then centrifuged at 10,000*g* for 5 min. The supernatant was collected; an equivalent amount of sample buffer [125 mM Tris–HCl (pH 6.8), 4% (w/v) SDS, 20% (w/v) glycerol, 10% (v/v) 2-ME, 0.1 mg/ml BPB] and the suspension was incubated at room temperature. In this step, half the supernatant was treated with glycosidases Endo H_f or PNGase F (New England Biolabs, Ipswich, MA) according to the manufacturers' procedure before adding the sample buffer. Proteins were separated on a 10% SDS–polyacrylamide gel by electrophoresis and then transferred to a PVDF membrane (Immobilon-FL; Millipore, Billerica, MA) followed by western blot analysis. Rabbit anti-HA antibody (Bethyl Laboratories, Montgomery, TX) was primarily used at a dilution of 1:5,000 in TBST [10 mM Tris–HCl (pH 8.0), 150 mM NaCl, 0.05% (v/v) Tween-20], and a goat anti-Rabbit IgG horse radish peroxidase (HRP) conjugate (American Qualex, San Clemente, CA) was used at a dilution of 1:5,000 in TBST. A chemiluminescent reaction was performed with Amersham ECL Plus Western Blotting Detection System (GE Healthcare, Buckinghamshire, UK), and the signal was detected using the lumino-image analyzer LAS-1000mini system (Fujifilm, Tokyo, Japan).

Fluorescence imaging by confocal laser scanning microscopy

The cultured cells were washed and suspended in distilled water to yield an optical density of 40 at 600 nm. The cell suspensions were observed with a confocal laser scanning microscope (LSM 5 PASCAL; Carl Zeiss, Oberkochen, Germany). Fluorescence images were acquired using the 488 nm line of an argon laser for excitation and a 505-nm band pass filter for emission.

Signalling assay and flow cytometry analysis

The cultured cells were washed and suspended in distilled water to yield an optical density of 10 at 600 nm. The cell suspensions and somatostatin (Calbiochem, Darmstadt, Germany) (added to yield final concentrations of 5, 10, 25, 50, 75, 100, 250, 500 and 750 nM, and 1, 2.5, 5 and 10 μM) were dispensed into 96-well cluster dishes containing SDM71 media. The plate was incubated at 30°C with shaking at 150 rpm for 4 h. The GFP expression levels in response to each signal transduction were analysed by a flow cytometer (FACSCanto II, Becton Dickinson and Co.). A total of 10,000 cells was analysed for each transformant. The green fluorescence signal was exited with a 488-nm blue laser and collected through a 530/30-nm band-pass filter, and the intensity was defined as the GFP-A mean of 10,000 cells. Assays were performed using three independent transformants.

Results and discussion

Expression of wild-type hSSTR5 and alanine-substituted mutants for two asparagine residues on the amino-terminus in S. cerevisiae

To investigate the importance of the asparagine residues at the 13th and 26th positions on the amino-terminal domains in hSSTR5, two asparagine residues were replaced with alanine residues. The expression plasmids for wild-type hSSTR5 and three resulting mutant receptors that have single (N13A or N26A) and a double substitution (N13/26A) were introduced into an IMFD-70 yeast strain.

Western blot analysis was initially performed with SDS-extracted fractions to examine the expression of the receptor proteins in yeast cells by using the anti-HA antibody. As shown in Fig. 1A, the major specific bands of the wild-type and mutant receptors

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010



Fig. 1 Western blot analysis of hSSTR5s expressed in yeast. Membrane preparations of hSSTR5s in yeast transformants were analysed by SDS/PAGE (10% gel) and immunoblotted with the HA monoclonal antibody (**A**). The same samples were treated with endoglycosidase (Endo H_f) (**B**). Lane 1: mock, lane 2: wild-type, lane 3: N13A single mutant, lane 4: N26A single mutant, lane 5: N13A and N26A double mutant.



Fig. 2 Localisation of wild-type and mutated hSSTR5s. Wild-type and mutated hSSTR5s were fused with GFP at each carboxy terminus. Yeast cells expressing the GFP-fused hSSTR5s were grown in SD-selectable media for 18 h. The cell suspensions were observed with a confocal laser scanning microscope. (**A**) wild-type, (**B**) N13A, (**C**) N26A, (**D**) N13A and N26A.

were confirmed; equal-sized bands were never detected in the case of yeast cells harbouring the mock vector, verifying that hSSTR5 and its mutants were expressed in the yeast cells. The wild-type receptor and single mutant receptors (N13A and N26A) were slightly displayed as subsequent specific bands just above the main bands, while the double mutant receptor (N13/26A) never displayed a similar band. Although the non-specific second minor band from the top showed overlaps, it appeared as the thick HA-specific band of the wild-type receptor when compared with the other mutant receptors. These receptor-specific bands with minor amounts but certainly higher molecular weights were probably considered as the glycosylated receptors on the asparagine residues at the 13th or 26th position.

To verify the glycosylation of the receptor proteins in the yeast cells, the same SDS-extracted fractions were treated with endoglycosidase (Endo H_f). Western blot analysis showed that all bands of presumed glycosylated-receptors disappeared (Fig. 1B). Another glycosidase treatment with PNGase F also exhibited similar results (data not shown). The results of these western blot analyses suggest that the wild-type hSSTR5 and the mutant receptors were surely expressed in yeast and were barely glycosylated at the 13th and 26th asparagine residues on the motifs with a slight degree of modification efficiency.

Observation of localisation of hSSTR5 mutants fused with a GFP tag by using confocal laser scanning microscopy

To investigate the localisation of the receptors in yeast cells, a GFP tag protein was fused to the wild-type hSSTR5 and mutant receptors at the carboxy terminus. Figure 2 shows the confocal laser scanning microscope images of the yeast cells harbouring the GFP-fused receptor expression plasmids. Green fluorescence was localised to the cell membrane at some levels in yeast cells expressing the wild-type hSSTR5-GFP fusion protein. All three mutant hSSTR5-GFP fusion proteins were also reasonably localised on the surface membranes in the yeast cells. These results indicated that the mutation of Asn13 and Asn26 residues did not affect the localisation on the yeast cell surface.

Evaluation of somatostatin-specific signalling ability of hSSTR5 mutants, using yeast-based GFP fluorescent reporter gene assay by flow cytometry

The IMFD-70 yeast strain constructed in this study was designed to robustly induce the expression of the *GFP* reporter gene under the control of the pheromone responsible *FIG1* promoter in response to ligand-specific signalling through a human receptor. Therefore, the ligand-specific signalling activation levels of human GPCRs could be easily and instantly measured with non-destructive cells on a flow cytometer. The yeast strain IMFD-70 was used for quantitative evaluation of the signalling ability of hSSTR5 responding to the somatostatin stimulation.

To evaluate the somatostatin-specific signalling ability of the wild-type hSSTR5 and its mutants, the yeast-based *GFP* reporter gene assay was carried out. Figure 3 shows the dose–response curves for somatostatin-specific signalling in IMFD-70 cells expressing wild-type hSSTR5 and mutant receptors (N13A, N26A and N13/26A). Wild-type hSSTR5 displayed obvious GFP fluorescence depending on various somatostatin concentrations in the yeast cells, and the dose-response of hSSTR5 signalling responding to the somatostatin-specific activation was thus confirmed. On the other hand, the single mutations in hSSTR5 (N13A and N26A) considerably decreased the dose–responses of somatostatin-specific signalling. Moreover, the double mutant of hSSTR5 (N13/26A) significantly and completely lost the ability to respond to somatostatin-specific signalling. In fact, the half maximal effective concentration (EC_{50}) values of the cells expressing the single mutant receptors were ~3-fold higher than those of the wild-type

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010



Fig. 3 Dose–response curves of signalling levels of wild-type and mutated hSSTR5s. All transformants were grown in SD selectable media for 18 h. The cell suspensions and each concentration of somatostatin were added into SDM71 media and incubated at 30°C for 4 h. The mean value of the green fluorescence signal of 10,000 cells analysed on flow cytometer is displayed. Data points represent the mean ± SEM obtained from three different experiments and are normalized to the fluorescence measure in the absence of ligand. multi: Mock, open square: wild-type, filled triangle: N13A, open circle: N26A, filled rhombus: N13A and N26A.

receptor-expressing cells (wild-type, 109 ± 11 nM; N13A, 335 ± 44 nM and N26A, 312 ± 44 nM), while the double mutant-expressing cells were incapable (N13/26A). In addition, the single substitutions of glutamine residues for asparagine residues (N13Q and N26Q) substantially decreased, and the double substitutions of glutamate, glutamic acid, lysine and phenylalanine residues for both asparagine residues (N13/26Q, N13/26E, N13/26K and N13/26F) did not exhibit the signalling activity of hSSTR5 either (data not shown). These results clearly show that the asparagine residues at the 13th and 26th positions in the amino-terminus of hSSTR5 are important for receptor function, although the properties of amino-acid side chain (*i.e.* charge or size) do not affect ligand binding. Hence, it might be that the oligosaccharides on amino-terminal domain of hSSTR5 concern the binding of somatostatin to receptor.

Finally, two asparagine residues of human SSTR5 in the amino-terminus exhibited a similar function to that of rat SSTR3 (*24*). The fact that hSSTR5 was barely N-glycosylated (Fig. 1) and high mannose oligosaccharides were generally attached in *S. cerevisiae* might be useful in furthering improvements in yeast-based GPCR analysis, for example, in engineering the enhancement of the glycosylation efficiency or to produce humanized glycoprotein in yeast cells (*29*). However, a multitude of reports on yeast-based GPCR analyses have demonstrated their availabilities (*4*, *5*, *7*, *30*); one, in particular, reported that the human adenosine A2a receptor could exert its function and localise in the plasma membrane without N-glycosylation in yeast (*31*). Even in the current study, somatostatin stimulation via human SSTR5 was coupled to the pheromone signalling pathway in yeast, exposing the apparent distinction of the signalling abilities between the wild-type receptor and its mutants.

Our work demonstrates the convenience of our yeast-based fluorescent signalling assay. In the case for somatostatin-specific signal transduction of rat SSTR3 in HEK293 cells, the inhibition of adenylyl cyclase activity was mediated by somatostatin-specific signalling via the α-subunits of the G_i family and the adenylyl cyclase activity-dependent cAMP concentrations were measured for quantification of the signalling (*19*). The determination of the cAMP production levels basically requires the activation of adenylyl cyclase with forskolin and a complicated multiple-step procedure, including cell washing, stopping cAMP accumulation, collecting intracellular cAMP with cell disruption, evaporation for cAMP enrichment, the use of a highly sensitive radiolabelled ligand and the generation of a standard curve. On the other hand, our yeast-based fluorescent signalling assay system could evaluate the somatostatin-specific hSSTR5 signalling with simple and instant manipulations merely by collection and direct analysis of non-destructive cells on the flow cytometer after incubation in a ligand-additive medium.

In conclusion, we showed the importance of two asparagine residues in the amino-terminus of human somatostatin receptor subtype-5 for somatostatin-specific signalling activation by using a yeast-based fluorescent reporter assay. This yeast-based system using a fluorescent reporter gene would be used by applying flow cytometric sorting to large-library screening, and will also be available for other human GPCRs and be beneficial for the simplification of experimental procedures in a GPCR signalling study.

Acknowledgements

The authors thank Prof. Shun'ichi Kuroda and Dr Kenji Tatematsu for their help.

Funding

This work was supported by a Grant-in-Aid for Scientific Research on Priority Areas (Life surveyor) and in part by a Special Coordination Funds for Promoting Science and Technology, Creation of Innovation Centres for Advanced Interdisciplinary Research Areas (Innovative Bioproduction Kobe) from the Ministry of Education, Culture, Sports, Science and Technology of Japan, and was funded in part by AS ONE Corporation.

Conflict of interest

None declared.

References

1. Heilker, R., Wolff, M., Tautermann, C.S., and Bieler, M. (2009) G-protein-coupled receptor-focused drug discovery using a target class platform approach. *Drug Discov. Today* **14**, 231–240
2. Kanagy, N.L. and Webb, R.C. (1996) Increased responsiveness and decreased expression of G proteins in

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010

deoxycorticosterone hypertension. *Hypertension* **27**, 740–745
3. Gohla, A., Schultz, G., and Offermanns, S. (2000) Role for G_{12}/G_{13} in agonist-induced vascular smooth muscle cell contraction. *Circ. Res.* **87**, 221–227
4. Stewart, G.D., Valant, C., Dowell, S.J., Mijaljica, D., Devenish, R.J., Scammells, P.J., Sexton, P.M., and Christopoulos, A. (2009) Determination of adenosine A1 receptor agonist and antagonist pharmacology using Saccharomyces cerevisiae: implications for ligand screening and functional selectivity. *J. Pharmacol. Exp. Ther.* **331**, 277–286
5. Minic, J., Sautel, M., Salesse, R., and Pajot-Augy, E. (2005) Yeast system as a screening tool for pharmacological assessment of g protein coupled receptors. *Curr. Med. Chem.* **12**, 961–969
6. Klein, C., Paul, J.I., Sauvé, K., Schmidt, M.M., Arcangeli, L., Ransom, J., Trueheart, J., Manfredi, J.P., Broach, J.R., and Murphy, A.J. (1998) Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. *Nat. Biotechnol.* **16**, 1334–1337
7. Klco, J.M., Nikiforovich, G.V., and Baranski, T.J. (2006) Genetic analysis of the first and third extracellular loops of the C5a receptor reveals an essential WXFG motif in the first loop. *J. Biol. Chem.* **281**, 12010–12019
8. Erlenbach, I., Kostenis, E., Schmidt, C., Serradeil-Le, Gal C., Raufaste, D., Dumont, M.E., Pausch, M.H., and Wess, J. (2001) Single amino acid substitutions and deletions that alter the G protein coupling properties of the V2 vasopressin receptor identified in yeast by receptor random mutagenesis. *J. Biol. Chem.* **276**, 29382–29392
9. Klco, J.M., Wiegand, C.B., Narzinski, K., and Baranski, T.J. (2005) Essential role for the second extracellular loop in C5a receptor activation. *Nat. Struct. Mol. Biol.* **12**, 320–326
10. Beukers, M.W., van Oppenraaij, J., van der Hoorn, P.P., Blad, C.C., den Dulk, H., Brouwer, J., and IJzerman, A.P. (2004) Random mutagenesis of the human adenosine A2B receptor followed by growth selection in yeast. Identification of constitutively active and gain of function mutations. *Mol. Pharmacol.* **65**, 702–710
11. Raynor, K., Murphy, W.A., Coy, D.H., Taylor, J.E., Moreau, J.P., Yasuda, K., Bell, G.I., and Reisine, T. (1993) Cloned somatostatin receptors: identification of subtype-selective peptides and demonstration of high affinity binding of linear peptides. *Mol. Pharmacol.* **43**, 838–844
12. Raynor, K., O'Carroll, A.M., Kong, H., Yasuda, K., Mahan, L.C., Bell, G.I., and Reisine, T. (1993) Characterization of cloned somatostatin receptors SSTR4 and SSTR5. *Mol. Pharmacol.* **44**, 385–392
13. Saito, T., Iwata, N., Tsubuki, S., Takaki, Y., Takano, J., Huang, S.M., Suemoto, T., Higuchi, M., and Saido, T.C. (2005) Somatostatin regulates brain amyloid beta peptide Abeta42 through modulation of proteolytic degradation. *Nat. Med.* **11**, 434–439
14. Lamberts, S.W., de Herder, W.W., Krenning, E.P., and Reubi, J.C. (1994) A role of (labeled) somatostatin analogs in the differential diagnosis and treatment of Cushing's syndrome. *J. Clin. Endocrinol. Metab.* **78**, 17–19
15. Ben-Shlomo, A. and Melmed, S. (2008) Somatostatin agonists for treatment of acromegaly. *Mol. Cell. Endocrinol.* **286**, 192–198
16. Jaquet, P., Saveanu, A., Gunz, G., Fina, F., Zamora, A.J., Grino, M., Culler, M.D., Moreau, J.P., Enjalbert, A., and Ouafik, L.H. (2000) Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. *J. Clin. Endocrinol. Metab.* **85**, 781–792
17. Lehle, L. and Bause, E. (1984) Primary Structural Requirements for N-Glycosylation and O-Glycosylation of Yeast Mannoproteins. *Biochim. Biophys. Acta* **799**, 246–251
18. Opdenakker, G., Rudd, P.M., Ponting, C.P., and Dwek, R.A. (1993) Concepts and principles of glycobiology. *FASEB J.* **7**, 1330–1337
19. Lanctot, P.M., Leclerc, P.C., Clément, M., Auger-Messier, M., Escher, E., Leduc, R., and Guillemette, G. (2005) Importance of N-glycosylation positioning for cell-surface expression, targeting, affinity and quality control of the human AT1 receptor. *Biochem. J.* **390**, 367–376
20. Mentesana, P.E. and Konopka, J.B. (2001) Mutational analysis of the role of N-glycosylation in alpha-factor receptor function. *Biochemistry* **40**, 9685–9694
21. Compton, S.J., Sandhu, S., Wijesuriya, S.J., and Hollenberg, M.D. (2002) Glycosylation of human proteinase-activated receptor-2 (hPAR2): role in cell surface expression and signalling. *Biochem. J.* **368**, 495–505
22. Hawtin, S.R., Davies, A.R., Matthews, G., and Wheatley, M. (2001) Identification of the glycosylation sites utilized on the V1a vasopressin receptor and assessment of their role in receptor signalling and expression. *Biochem. J.* **357**, 73–81
23. Møller, L.N., Stidsen, C.E., Hartmann, B., and Holst, J.J. (2003) Somatostatin receptors. *Biochim. Biophys. Acta* **1616**, 1–84
24. Nehring, R.B., Richter, D., and Meyerhof, W. (2000) Glycosylation affects agonist binding and signal transduction of the rat somatostatin receptor subtype 3. *J. Physiol. (Paris)* **94**, 185–192
25. Ishii, J., Tanaka, T., Matsumura, S., Tatematsu, K., Kuroda, S., Ogino, C., Fukuda, H., and Kondo, A. (2008) Yeast-based fluorescence reporter assay of G protein-coupled receptor signalling for flow cytometric screening: FAR1-disruption recovers loss of episomal plasmid caused by signalling in yeast. *J. Biochem.* **143**, 667–674
26. Gietz, D., St Jean, A., Woods, R.A., and Schiestl, R.H. (1992) Improved method for high efficiency transformation of intact yeast cells. *Nucleic Acids Res.* **20**, 1425
27. Akada, R., Kitagawa, T., Kaneko, S., Toyonaga, D., Ito, S., Kakihara, Y., Hoshida, H., Morimura, S., Kondo, A., and Kida, K. (2006) PCR-mediated seamless gene deletion and marker recycling in Saccharomyces cerevisiae. *Yeast* **23**, 399–405
28. Ishii, J., Izawa, K., Matsumura, S., Wakamura, K., Tanino, T., Tanaka, T., Ogino, C., Fukuda, H., and Kondo, A. (2009) A simple and immediate method for simultaneously evaluating expression level and plasmid maintenance in yeast. *J. Biochem.* **145**, 701–708
29. Chiba, Y. and Akeboshi, H. (2009) Glycan engineering and production of 'humanized' glycoprotein in yeast cells. *Biol. Pharm. Bull.* **32**, 786–795
30. Pausch, M.H., Lai, M., Tseng, E., Paulsen, J., Bates, B., and Kwak, S. (2004) Functional expression of human and mouse P2Y12 receptors in Saccharomyces cerevisiae. *Biochem. Biophys. Res. Commun.* **324**, 171–177
31. Butz, J.A., Niebauer, R.T., and Robinson, A.S. (2003) Co-expression of molecular chaperones does not improve the heterologous expression of mammalian G-protein coupled receptor expression in yeast. *Biotechnol. Bioeng.* **84**, 292–304

Downloaded from http://jb.oxfordjournals.org at Kobe University on June 7, 2010